Axsome Therapeutics Secures $24 Million Growth Capital Loan Facility Led by Silicon Valley Bank
March 06, 2019 07:00 ET
|
Axsome Therapeutics, Inc.
$46 million total raised in recent financings extends cash runway into at least 4Q 2021 Current financial position fully funds all five ongoing clinical trials NEW YORK, March 06, 2019 (GLOBE...
Axsome Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results on March 14, 2019
March 05, 2019 07:00 ET
|
Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Thursday, March 14, 2019 at 8:00 AM Eastern Time NEW YORK, March 05, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
Axsome Therapeutics Initiates MOMENTUM Phase 3 Trial of AXS-07 in Migraine
March 04, 2019 07:00 ET
|
Axsome Therapeutics, Inc.
First patient enrolled in the MOMENTUM study Trial being conducted under FDA Special Protocol Assessment (SPA) Topline results anticipated in 1Q 2020 NEW YORK, March 04, 2019 (GLOBE NEWSWIRE) --...
Endonovo Therapeutics Announces New Website Launch
February 27, 2019 08:00 ET
|
Endonovo Therapeutics, Inc.
The completely redesigned website offers visitors deeper insight into the Company's core product, SofPulse® LOS ANGELES, CA, Feb. 27, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB:...
Axsome Therapeutics Receives FDA Agreement under Special Protocol Assessment (SPA) for the MOMENTUM Phase 3 Trial of AXS-07 in Migraine
February 06, 2019 07:00 ET
|
Axsome Therapeutics, Inc.
FDA agreement achieved on Phase 3 trial design, endpoints, and statistical approach Trial to enroll patients with a history of inadequate response to prior migraine treatments Trial initiation...
Axsome Therapeutics Initiates Phase 2 Trial of AXS-12 in Narcolepsy
January 30, 2019 07:00 ET
|
Axsome Therapeutics, Inc.
Topline results anticipated in 2Q 2019 NEW YORK, Jan. 30, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies...
Axsome Therapeutics Raises $23.3 Million Under Existing ATM Facility
January 07, 2019 18:35 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in Phase 2 Trial in Major Depressive Disorder
January 07, 2019 06:00 ET
|
Axsome Therapeutics, Inc.
Demonstrated statistically significant improvement in MADRS scores compared to active comparator (p<0.001 on primary endpoint) Rapid improvement in depressive symptoms demonstrating statistically...
Axsome Therapeutics Provides Year End 2018 Clinical Update
December 27, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
FDA clearance of IND received for Phase 2 trial of AXS-12 in narcolepsy Phase 2 results of AXS-05 in major depressive disorder on track for early January 2019 Phase 3 results of AXS-05 in treatment...
Axsome Therapeutics to Present at Biotech Showcase 2019
December 18, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...